According to the results of the Pharma & Hospital Report study, which analyzes the local pharmaceutical market, Cegedim Customer Information estimates that the volume of medicines dispensed to patients in Romania totaled 717.3 million units in the last 12 months ended June 2025, approximately 1% more than the dispensed volumes in the reference period (July 2023-June 2024).
The total number of treatment days increased by 2,5%, driven by a 2.4% increase in retail, while the number of hospital treatment days increased by 8.0%.
During the same period of time, the value of medicines dispensed to patients in Romania increased by 13.2%, reaching RON 36.2 billion (EUR 7.26 billion) at the wholesale price level. Isolating the impact of the CVR and CV programs, the value of prescription medicines in retail pharmacies increased by 11.1% compared to the reference period, amounting to RON 18.49 billion (EUR 3.71 billion).
Pharma market evolution in Volume and in Value
In the second quarter of 2025, the total volume of medicines dispensed to patients reached 172.2 million units, marking a 1.1% increase compared to the same quarter in 2024. This modest growth was primarily fueled by a 1.2% rise in the retail channel, while hospital dispensations declined by 1.0%. Analyzing the segments, prescription medications in pharmacies remained flat (0.2%), whereas over-the-counter (OTC) products, which include both OTC drugs and nutritional supplements, saw a small increase of 3.0%.
The total value of medicines dispensed to patients amounted to RON 9.2 billion lei, 12.3% up compared to the second quarter of 2024. This growth was driven by a 12.2% increase in the retail sector and a 12.5% increase in hospital dispensations. Within the retail channel, the value of prescription (Rx) medicines rose by 12.8%, while over-the-counter (OTC) products increased by 10.7%.
Notably, retail Rx drugs related to cost-volume contracts increased by 26.5%, while those under cost-volume-result contracts advanced by 31.8%. Other Rx medicines in retail advanced by 10.3% compared to the second quarter of 2024.
Main players in the local pharmaceutical market
In the second quarter of 2025, the ranking of the top 3 corporations by volume remained unchanged. Sun Pharma (including Terapia) maintained its lead with 17.9 million units, followed by Zentiva (including Labormed and Alvogen) with 15.1 million units, and Servier (including Egis) with 10.9 million units.
In the second quarter of 2025, the top three hierarchy by value hasn’t changed vs the previous quarter. AstraZeneca maintained the leading position with RON 513.0 million, followed by Sun Pharma (RON 410.0 million, including Terapia) and Zentiva (including Labormed and Alvogen) with RON 374.9 million.
To consult the complete information on the Romanian pharmaceutical market evolution in the second quarter of 2025 as well as the top players on this market during the same period, access directly our press release.
We also invite you to consult an executive summary of the study for the mentioned period, with graphical representations of the data presented in our article.
Pharma & Hospital Report, a reference study in the analysis of the pharmaceutical market in Romania, has been carried out since 1996.
